# Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

> **NCT06226662** · PHASE2 · NOT_YET_RECRUITING · sponsor: **NovelMed Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

## Interventions

- **DRUG:** NM8074
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06226662
- **Lead sponsor:** NovelMed Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-10
- **Final completion:** 2028-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226662, "Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06226662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*